TA-650
TA-650 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Registry-listed formulations
This catalogue entry has no confirmed scientific concept.
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
4 source entries across 4 studies. This list may not include all unresolved or historical entries.
- TA-650Registry intervention
Linked study entry; product equivalence not established
View study and source - TA-650Registry intervention
Linked study entry; product equivalence not established
View study and source - TA-650Registry intervention
Linked study entry; product equivalence not established
View study and source - TA-650Registry intervention
Linked study entry; product equivalence not established
View study and source
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
4 of 4 finished
0.0%
0 ended early
0
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
Clinical Trials (4)
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
All 4 trials loaded
Drug Details
- Intervention Type
- Drug
- Total Trials
- 4